Hunting Hill Global Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hunting Hill Global Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,491	Closed	-$326K	–	98
2025 Q4	$326K	Hold	5,491	–	–	0.22%	71
2025 Q3	$297K	Hold	5,491	–	–	0.08%	85
2025 Q2	$302K	Hold	5,491	–	–	0.08%	97
2025 Q1	$388K	Hold	5,491	–	–	0.24%	67
2024 Q4	$361K	Hold	5,491	–	–	0.13%	67
2024 Q3	$386K	Hold	5,491	–	–	0.37%	50
2024 Q2	$452K	Hold	5,491	–	–	0.2%	64
2024 Q1	$480K	Buy	+5,491	New	+$492K	0.24%	76

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hunting Hill Global Capital's BMRN Position: Q1 2026 in Review

Hunting Hill Global Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 5,491 shares — an estimated $326K sold.

Hunting Hill Global Capital first reported a position in BMRN in Q1 2024 and held it in 8 quarters. The position peaked at $480K in Q1 2024. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Hunting Hill Global Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Hunting Hill Global Capital sold 5,491 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $326K.
Hunting Hill Global Capital first reported a position in BioMarin Pharmaceuticals in Q1 2024 and held it in 8 quarters.
Hunting Hill Global Capital's BioMarin Pharmaceuticals position peaked at $480K in Q1 2024.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Hunting Hill Global Capital's 13F filing for Q1 2026, filed 15 May 2026.